Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. | Becker et al. Arthritis Research Therapy 2010 12 R63 http content 12 2 R63 RESEARCH ARTICLE Open Access The urarce-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout the CONFIRMS trial Michael A Becker 1 H Ralph Schumacher2 Luis R Espinoza3 Alvin F Wells4 Patricia MacDonald5 Eric Lloyd5 and Christopher Lademacher6 Abstract Introduction The purpose of this study was to compare urate-lowering UL efficacy and safety of daily febuxostat and allopurinol in subjects with gout and serum urate sUA mg dL in a six-month trial. Methods Subjects n 2 269 were randomized to febuxostat 40 mg or 80 mg or allopurinol 300 mg 200 mg in moderate renal impairment . Endpoints included the proportion of all subjects with sUA mg dL and the proportion of subjects with mild moderate renal impairment and sUA mg dL. Safety assessments included blinded adjudication of each cardiovascular CV adverse event AE and death. Results Comorbidities included renal impairment 65 obesity 64 hyperlipidemia 42 and hypertension 53 . In febuxostat 40 mg febuxostat 80 mg and allopurinol groups primary endpoint was achieved in 45 67 and 42 respectively. Febuxostat 40 mg UL was statistically non-inferior to allopurinol but febuxostat 80 mg was superior to both P . Achievement of target sUA in subjects with renal impairment was also superior with febuxostat 80 mg 72 P compared with febuxostat 40 mg 50 or allopurinol 42 but febuxostat 40 mg showed greater efficacy than allopurinol P . Rates of AEs did not differ across treatment groups. Adjudicated APTC CV event rates were for febuxostat 40 mg and for both febuxostat 80 mg and allopurinol. One death occurred in each febuxostat group and three in the allopurinol group. Conclusions Urate-lowering efficacy of febuxostat 80 mg exceeded that of febuxostat 40 mg and allopurinol 300 200 mg which were comparable. In subjects with mild moderate renal impairment both .
